Supporting Information

Screening on-chip fabricated nanoparticles for penetrating bloodbrain barrier

Qinghong Hou,^{‡a, b, c} Lina Zhu, ^{‡*a} Le Wang,^b Xiaoyan Liu,^b Feng Xiao,^b Yangzhouyun Xie,^b Wenfu Zheng,^{*c} and Xingyu Jiang,^{*b}

This SI includes the following contents: Fig. S1-9



D-T7 peptide sequence: D-HRPYIAHC



TGN peptide sequence: TGNYKALHPHNGC



CGN peptide sequence: D-CGNHPLAKYNGT



DSPE-PEG-TGN



DSPE-PEG-CGN



DSPE-PEG-D-T7

Fig. S1 Structural formula of D-T7, TGN, and CGN peptides and DSPE-PEG-D-T7, DSPE-PEG-TGN, and DSPE-PEG-CGN



Fig. S2 Structural formula of T7, TAT, and GSH peptides and DSPE-PEG-T7, DSPE-PEG-TAT, and DSPE-PEG-GSH.



Fig. S3 Mass spectra of TGN, CGN, and D-T7 peptides and DSPE-PEG-TGN, DSPE-PEG-CGN, and DSPE-PEG-D-T7.



Fig. S4 Mass spectra of T7, TAT, and GSH peptides and DSPE-PEG-T7, DSPE-PEG-TAT, and DSPE-PEG-GSH.



Fig. S5 Zeta potential of the different peptide-lipids@PL nanoparticles analyzed by DLS.



Fig. S6 Fluorescent imaging of organs *ex vivo* 24 h after the injection of DiR-labelled nanoparticles.



Fig. S7 Confocal microscopy image of bEnd.3 cells (A) and hippocampal neurons (B) co-cultured with various nanoparticles for 24 hours.



Fig. S8 The biosafety of PBS, LTG, lipids@PL nanoparticles and D-T7-lipids@PL nanoparticles was evaluated by blood routine and blood biochemical analysis.



Fig. S9 Biosafety of lipids@PL nanoparticles and D-T7-lipids@PL nanoparticles was evaluated by H&E staining analysis.